Yan Z, Xing X-W, Zhang X-G, Wang X, Kuang J-G, Lu Q-H
Department of Cardiology, The Second Hospital of Shandong University, Cheeloo College of Medicine, Jinan, Shandong, China.
Eur Rev Med Pharmacol Sci. 2023 Mar;27(6):2341-2349. doi: 10.26355/eurrev_202303_31769.
There is limited data about the use of a Judkins left (JL) 3.5 guiding catheter for routine transradial right coronary artery (RCA) percutaneous coronary intervention (PCI). This study investigated the safety and efficacy of JL3.5 for RCA PCI.
Patients with acute coronary syndrome (ACS) who underwent transradial RCA PCI between November 2019 and November 2020 at the Second Hospital of Shandong University were included. The study retrospectively compared JL 3.5 vs. other routine guiding catheters (GCs), including Judkins right (JR) 4.0 and Amplatz (left). Logistic multivariable analysis was used to analyze the factors associated with transradial RCA PCI success rate, in-hospital complications, and extra support.
The study included 311 patients: 136 in the routine GC group and 175 in the JL 3.5 group. There were no significant differences between the two groups regarding in-hospital complications, extra support technics, or success. The multivariable analyses showed that coronary chronic total occlusion (CTO) was negatively associated with intervention success (OR = 0.06, 95% CI: 0.016-0.248, p < 0.001) but positively with extra support (OR = 8.74, 95% CI: 1.518-50.293, p = 0.015). Tortuosity was associated with extra support (OR = 16.50, 95% CI: 3.324-81.589, p = 0.001). In the JL 3.5 group, the left ventricular ejection fraction (OR = 1.11, 95% CI: 1.03-1.20, p = 0.006), CTO (OR = 0.07, 95% CI: 0.008-0.515, p = 0.009), and tortuosity (OR = 0.17, 95% CI: 0.03-0.95, p = 0.043) were independently associated with intervention success.
JL 3.5 appears to be as safe and effective as the JR 4.0 and Amplatz (left) catheters for RCA PCI. When using the JL 3.5 catheter for RCA PCI, heart function, CTO, and tortuosity should be considered.
关于使用Judkins左(JL)3.5引导导管进行常规经桡动脉右冠状动脉(RCA)经皮冠状动脉介入治疗(PCI)的数据有限。本研究调查了JL3.5用于RCA PCI的安全性和有效性。
纳入2019年11月至2020年11月在山东大学第二医院接受经桡动脉RCA PCI的急性冠状动脉综合征(ACS)患者。本研究回顾性比较了JL 3.5与其他常规引导导管(GCs),包括Judkins右(JR)4.0和Amplatz(左)。采用逻辑多变量分析来分析与经桡动脉RCA PCI成功率、院内并发症及额外支持相关的因素。
本研究纳入311例患者:常规GC组136例,JL 3.5组175例。两组在院内并发症、额外支持技术或成功率方面无显著差异。多变量分析显示,冠状动脉慢性完全闭塞(CTO)与介入成功率呈负相关(OR = 0.06,95%CI:0.016 - 0.248,p < 0.001),但与额外支持呈正相关(OR = 8.74,95%CI:1.518 - 50.293,p = 0.015)。血管迂曲与额外支持相关(OR = 16.50,95%CI:3.324 - 81.589,p = 0.001)。在JL 3.5组中,左心室射血分数(OR = 1.11,95%CI:1.03 - 1.20,p = 0.006)、CTO(OR = 0.07,95%CI:0.008 - 0.515,p = 0.009)和血管迂曲(OR = 0.17,95%CI:0.03 - 0.95,p = 0.043)与介入成功率独立相关。
对于RCA PCI,JL 3.5似乎与JR 4.0和Amplatz(左)导管一样安全有效。在使用JL 3.5导管进行RCA PCI时,应考虑心功能、CTO和血管迂曲情况。